Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2007

View Archived Issues

Recombinant T-cell receptor ligand to be examined in phase I trial for multiple sclerosis

Fovea licenses RdCVF therapy for retinal degeneration

Nicholas Piramal and Lilly sign new drug development agreement

Intercell completes acquisition of Pelias

European grant for VASOPLUS consortium's proangiogenesis program

Third interim analysis due in pivotal breast cancer study of tesmilifene

Cleveland BioLabs enters research partnership with Roswell Park Cancer Institute

Novo Nordisk focuses R&D on therapeutic proteins

RX-100 shown to protect against lethal whole-body radiation

U.S. orphan drug designation for LX-211 in uveitis

Dermylex available in Canada for psoriasis

CAT-192 ineffective in early stage systemic sclerosis

BMS-201038 effective in familial hypercholesterolemia

Novel agents for treating endocrine-related disorders disclosed in recent patents

New treatment options for inflammatory disorders disclosed in recent patent literature

Recent Actelion patent discloses new agents for transplant rejection and graft-versus-host disease

Omega-3 polyunsaturated fatty acids may regulate the nociceptive TRPV1 channel

First European approval for Wellbutrin XR

Neupro now approved in Europe for all stages of Parkinson's disease

FDA approves Lialda in ulcerative colitis

New European approval for Keppra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...